Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
43.56
-1.77 (-3.90%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Structure Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Structure Therapeutics stock have an average target of 103.17, with a low estimate of 65 and a high estimate of 140. The average target predicts an increase of 136.85% from the current stock price of 43.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Structure Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 7 | 7 | 7 | 8 |
| Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 11 | 12 | 12 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $101 | Strong Buy | Initiates | $101 | +131.86% | Apr 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $114 → $100 | Strong Buy | Maintains | $114 → $100 | +129.57% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $114 | Strong Buy | Maintains | $90 → $114 | +161.71% | Mar 2, 2026 |
| Citizens | Citizens | Buy Maintains $120 → $113 | Buy | Maintains | $120 → $113 | +159.41% | Feb 27, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $65 → $105 | Buy | Maintains | $65 → $105 | +141.05% | Jan 22, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
42.50K
EPS This Year
-1.76
from -2.39
EPS Next Year
-2.20
from -1.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 525,000 | ||||||
| Avg | n/a | 42,503 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.39 | -1.61 | ||||||
| Avg | -1.76 | -2.20 | ||||||
| Low | -2.19 | -2.86 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.